Regeneron Pharmaceuticals Inc. and Samsung Bioepis Co. Ltd. have told a West Virginia federal court they reached an agreement to end patent infringement claims brought by Regeneron over a biosimilar of its eye medication Eylea.

The companies said in a stipulation filed Wednesday they've agreed to resolve all issues between them and release a preliminary injunction bond over Samsung Bioepis' 2-milligram aflibercept product.

The claims are part of multidistrict litigation comprising a group of lawsuits brought by Regeneron against rivals over their Eylea biosimilars. Eylea, which Regeneron has described as its "flagship product," treats certain angiogenic eye disorders. The other companies targeted by Regeneron's claims include Amgen Inc., Biocon Biologics and Sandoz.

Counsel for the parties did not immediately respond to requests for comment Thursday.

Regeneron is represented by David I. Berl, Arthur John Argall III, Thomas S. Fletcher, Christian J. Gladden-Sorensen, Kathryn Schleckser Kayali, Rhochelle Krawetz, Shaun P. Mahaffy, Charles McCloud, Adam Pan and Andrew V. Trask of Williams & Connolly LLP, Jacob E. Hartman of Kellogg Hansen Todd Figel & Frederick PLLC, and Priyata Patel and Elizabeth Stotland Weiswasser of Paul Weiss Rifkind Wharton & Garrison LLP.

Samsung Bioepis is represented by Raymond N. Nimrod, Laura Fairneny and Zachariah Summers of Quinn Emanuel Urquhart & Sullivan LLP, and Frank Simmerman Jr., Frank E. Simmerman III and Chad Taylor of Simmerman Law Office PLLC, and Sandra K. Law of Schrader Duff Law & Lowe PLLC.

The case is In re: Aflibercept Patent Litigation, case number 1:24-md-3103, in the U.S. District Court for the Northern District of West Virginia.